Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) EBITDA (2019 - 2025)

Historic EBITDA for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$265689.0.

  • Bioadaptives' EBITDA fell 11788.32% to -$265689.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 24648.51%. This contributed to the annual value of -$602090.0 for FY2024, which is 16301.21% down from last year.
  • Per Bioadaptives' latest filing, its EBITDA stood at -$265689.0 for Q3 2025, which was down 11788.32% from -$279219.0 recorded in Q2 2025.
  • In the past 5 years, Bioadaptives' EBITDA registered a high of -$18975.0 during Q1 2023, and its lowest value of -$337339.0 during Q4 2024.
  • Its 5-year average for EBITDA is -$141213.1, with a median of -$121941.0 in 2024.
  • As far as peak fluctuations go, Bioadaptives' EBITDA tumbled by 89704.93% in 2021, and later skyrocketed by 8911.08% in 2023.
  • Bioadaptives' EBITDA (Quarter) stood at -$177734.0 in 2021, then soared by 84.64% to -$27302.0 in 2022, then tumbled by 126.3% to -$61784.0 in 2023, then crashed by 446.0% to -$337339.0 in 2024, then rose by 21.24% to -$265689.0 in 2025.
  • Its EBITDA stands at -$265689.0 for Q3 2025, versus -$279219.0 for Q2 2025 and -$249148.0 for Q1 2025.